文献速递产科母胎医学

无细胞DNA检测胎儿RhD基因型在美国RhD阴性孕妇中的临床表现

Clinical Performance of Cell-Free DNA for Fetal RhD Detection in RhD-Negative Pregnant Individuals in the United States.
PubMed 文献 · Obstet Gynecol · 2025-02-27

本研究为美国四家医疗中心的回顾性队列研究,纳入2020年8月至2023年11月401例未致敏RhD阴性孕妇,评估基于定量计数模板的新一代测序无细胞DNA检测胎儿RHD基因型的性能;结果显示与新生儿RhD血清学100%一致,灵敏度、特异度、阳性预测值、阴性预测值均为100%,支持将cfDNA筛查作为预防性RhIG的替代选择。

要点

  • cfDNA检测胎儿RHD与新生儿血清学100%一致,灵敏度、特异度、阳性预测值、阴性预测值均为100%。
  • 93.1%的cfDNA提示RhD阳性胎儿的孕妇接受产前RhIG,而cfDNA提示RhD阴性胎儿的孕妇为75.0%。
  • 作者认为该检测可作为预防性RhIG的替代选择,仅在有医学指征时使用RhIG。

核心结论

  • 该cfDNA检测胎儿RhD状态高度准确,401例种族和民族多样化的孕妇中无假阳性或假阴性结果,所有活产均完成随访。

研究设计与样本

  • 回顾性队列研究,在美国四家医疗中心开展,纳入2020年8月至2023年11月接受临床照护的401例未致敏RhD阴性孕妇。
  • 采用同一新一代测序定量计数模板cfDNA胎儿RhD检测,Rh免疫球蛋白(RhIG)由临床医生酌情给予。

主要发现

  • D抗原cfDNA结果与新生儿血清学100%一致,灵敏度100%、阳性预测值100%(95%CI 98.6-100%),特异度100%、阴性预测值100%(95%CI 97.4-100%)。
  • 10例孕妇经cfDNA分析发现非RHD基因缺失,包括RhDΨ(n=5)和RHD-CE-D杂交变异(n=5)。
  • cfDNA提示RhD阳性胎儿的孕妇中93.1%接受产前RhIG,而cfDNA提示RhD阴性胎儿的孕妇中为75.0%。

关键数值与推荐

  • 灵敏度100%、阳性预测值100%(95%CI 98.6-100%),特异度100%、阴性预测值100%(95%CI 97.4-100%)。
  • cfDNA提示RhD阳性胎儿的孕妇产前RhIG使用率93.1%,cfDNA提示RhD阴性胎儿的孕妇为75.0%。

临床怎么用

  • 作者认为本研究及既往研究支持推荐将cfDNA胎儿Rh状态筛查作为所有未致敏RhD阴性个体的预防性RhIG替代选择,从而实现更高效、有针对性的产前保健,仅在有医学指征时给予RhIG。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the performance of a cell-free DNA (cfDNA) assay that uses next-generation sequencing with quantitative counting templates for the clinical detection of the fetal RHD genotype in a diverse RhD-negative pregnant population in the United States. METHODS: This retrospective cohort study was conducted in four U.S. health care centers. The same next-generation sequencing quantitative counting template cfDNA fetal RhD assay was offered to nonalloimmunized RhD-negative pregnant individuals as part of clinical care. Rh immune globulin (RhIG) was administered at the discretion of the clinician. The sensitivity, specificity, and accuracy of the assay were calculated considering the neonatal RhD serology results. RESULTS: A total of 401 nonalloimmunized RhD-negative pregnant individuals who received clinical care in the period from August 2020 to November 2023 were included in the analysis. The D antigen cfDNA result was 100% concordant with the neonatal serology, resulting in 100% sensitivity, 100% positive predictive value (95% CI, 98.6-100% for both), 100% specificity, and 100% negative predictive value (95% CI, 97.4-100% for both). There were 10 pregnant individuals in whom the cfDNA analysis identified a non- RHD gene deletion, including RhDΨ (n=5) and RHD-CE-D hybrid variants (n=5). Rh immune globulin was administered antenatally to 93.1% of pregnant individuals, with cfDNA results indicating an RhD-positive fetus compared with 75.0% of pregnant individuals with cfDNA results indicating an RhD-negative fetus, signifying that clinicians were using the cfDNA results to guide pregnancy management. CONCLUSION: This next-generation sequencing with quantitative counting templates cfDNA analysis for detecting fetal RhD status is highly accurate with no false-positive or false-negative results in 401 racially and ethnically diverse pregnant individuals with 100% follow-up of all live births. This study and prior studies of this assay support a recommendation to offer cfDNA screening for fetal Rh status as an alternative option to prophylactic RhIG for all nonalloimmunized RhD-negative individuals, which will result in more efficient and targeted prenatal care with administration of RhIG only when medically indicated.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Mateus-Nino JF, Wynn J, Wiggins-Smith J, et al. Clinical Performance of Cell-Free DNA for Fetal RhD Detection in RhD-Negative Pregnant Individuals in the United States. Obstet Gynecol. 2025. PMID: 40014864. doi:10.1097/AOG.0000000000005850

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。